

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	09/110,376
Filing Date	May 12, 1998
First Named Inventor	Cohen
Group Art Unit	1643
Examiner Name	
Attorney Docket Number	

Sheet 2 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

1999 Examine Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HE	1	R. TSUNODA et al, "Emperipolesis of Lymphoid Cells by Human Follicular Dendritic Cells in Vitro," <i>Virchows Archiv. B Cell Pathol</i> , 1992, 62: 69-78.	
	2	A. WEISSMAN et al, "Role of the Zeta Chain in the Expression of the T Cell Antigen Receptor: Genetic Reconstitution Studies," <i>The EMBO Journal</i> , 1989, 8(12): 3651-3656	
	3	U. KIM, "Pathogenesis and Characteristics of Spontaneously Metastasizing Mammary Carcinomas and the General Principle of Metastasis," <i>J. of Surgical Oncology</i> , 1986, 33: 151-165	
	4	H. O'NEILL et al, "Germline Transcription and Expression of Tcrb-V8 Genes in Peripheral Mouse Lymphoid Tissues," <i>Immunogenesis</i> , 1995, 42: 309-314	
	5	G. BASI et al, "Antibodies to Soluble Human T Cell Receptor β Chain Recognize Multiple Epitopes on Cell Surface TCR," <i>Journal of Immunological Methods</i> , 1992, 155: 175-191	
	6	D. CENTER et al, "Interleukin 16 and its function as a CD4 Ligand," <i>Immunology Today</i> , 1996, 17(10): 476-481	
	7	S. MCCracken et al, "An Alternative Pathway for Expression of p56 ^{lck} from Type I Promoter Transcripts in Colon Carcinoma," <i>Oncogene</i> , 1997, 15: 2929-2937	✓
	8	I. FIDLER, "Critical Factors in the Biology of Human Cancer Metastasis: Twenty-eighth G. H. A. Clowes Memorial Award Lecture," <i>Cancer Research</i> , 1990, 50: 6130-6138	
	9	M. DAVIS, "T Cell Receptor Gene Diversity and Selection," <i>Annual Review of Biochemistry</i> , 1990, 59: 475-496	
	10	U. LATZA et al, "Ber-EP4: New Monoclonal Antibody which Distinguishes Epithelia from Mesothelia," <i>J. Clin. Pathol.</i> , 1990, 43: 213-219	
HE	11	J. PUGIN et al, "Lipopolysaccharide Activation of Human Endothelial and Epithelial Cells is Mediated by Lipopolysaccharide-binding Protein and Soluble CD14," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90: 2744-2748	

Examiner
Signature

Yvonne Epler

Date
Considered

3/22/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	09/110,376
Filing Date	May 12, 1998
First Named Inventor	Cohen
Group Art Unit	1643
Examiner Name	
Attorney Docket Number	

Sheet 23 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	12
HE	12	C. BLEUL et al, "The HIV Coreceptors CXCR4 and CCR5 Are Differentially Expressed and Regulated on Human T Lymphocytes," <u>Proc. Natl. Acad. Sci. USA</u> , 1997, 94:1925-1930	
	13	E. RUOSLAHTI, "How Cancer Spreads," <u>Scientific American</u> , 1996, Sept., 72-77	
	14	U. KIM et al, "Immunological Escape Mechanism in Spontaneously Metastasizing Mammary Tumors," <u>Proc. Natl. Acad. Sci. USA</u> , 1975, 72(3):1012-1016	
	15	S. COHEN et al, "Capacity of Nonparenchymal Liver Cells to Control Metastasis" <u>NK Cells in the Liver</u> , R.G. Landes Company, Austin, 1995, 71-100	
	16	T. SPRINGER, "Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm," <u>Cell</u> , 1994, 76:301-314	
	17	S. LATOUR et al, "Differential Intrinsic Enzymatic Activity of Syk and Zap-70 Protein-Tyrosine Kinases," <u>The Journal of Biological Chemistry</u> , 1996, 271(37):22782-22790	
	18	S. CANDEIAS et al, "T Cell Receptor VB8.2 Gene Germ-line Transcription: An Early Event of Lymphocyte Differentiation," <u>Eur. J. Immunol.</u> , 1994, 24:3073-3081	
	19	E. YEFENOF et al, "Cancer Dormancy: Isolation and Characterization of Dormant Lymphoma Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 1993, 90:1829-1833	
	20	S. LEE et al, "Ly-6A is Required for T CELL Receptor Expression and Protein Kinase Fyn Activity," <u>The EMBO JOURNAL</u> , 1994, 13(9):2167-2176	
	21	M. OMARY et al, "HIV-1 Infection and Expression in Human Colonic Cells: Infection and Expression in CD4+ and CD4- Cell Lines," <u>AIDS</u> , 1991, 5(3)275-281	
HE	22	U. KIM et al, "Selective Suppression of T Cell Function in Normal Rats Simulating the T-Independent Antitumor and Antimetastatic Reaction of Nude Mice Against Metastasizing Rat Mammary Carcinomas," <u>Immune-Deficient Animals 4th Int. Workshop on Immune-Deficient Animals in Exp. Res.</u> , Chexbres, 1982, 235-238	

Examiner Signature

Gymne Eyer

Date Considered

3/22/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

6

Complete If Known

Application Number	09/110,376
Filing Date	May 12, 1998
First Named Inventor	Cohen
Group Art Unit	1643
Examiner Name	
Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T ²
HC	34	O. KANAGAWA, "In Vivo T Cell Tumor Therapy with Monoclonal Antibody Directed to the VB Chain of T Cell Antigen Receptor," <u>J. Exp. Med.</u> , 1989, 170:1513-1519	
	35	R. MUISE-HELMERICKS et al, "Identification of a Novel Repressive Element in the Proximal Lck Promoter," <u>The Journal of Biological Chemistry</u> , 1995, 270(46):27538-27543	
	36	C. NG et al, "Application of a T Cell Receptor Antibody BF1 for Immunophenotypic Analysis of Malignant Lymphomas," <u>American Journal of Pathology</u> , 1988, 132(2):365-371	
	37	I. FIDLER et al, "Metastasis Results from Preexisting Variant Cells within a Malignant Tumor," <u>Science</u> , 1977, 197:893-895	
	38	N. WANG et al, "Characterization of High- and Low- Metastatic Clones Derived from a Methylcholanthrene- induced Murine Fibrosarcoma," <u>Cancer Research</u> , 1982, 42:1046-1051	
	39	F. SANGER, "DNA Sequencing with Chain- terminating Inhibitors," <u>Proc. Natl. Acad. Sci. USA</u> , 1977, 74(12):5463-5467	
	40	S. GHOSH, "A Tumor-associated Organ-specific Antigen Characteristic of Spontaneously Metastatic Rat Mammary Carcinomas," <u>JNCI</u> , 1979, 62(5):1229-1233	
	41	Barberá-Guillem et al, "Selective Implantation and Growth in Rats and Mice of Experimental Liver Metastasis in Acinar Zone One," <u>Cancer Research</u> , 1989, 49:4003-4010	
	42	S. YASAMURA et al, <u>Proc. Annu. Meet. Am. Assoc. Cancer Res.</u> , 1992, 33:A 290	
	43	U. KIM et al, "Conversion of MMTV-Induced Mouse Mammary Tumor and EJ-ras Transformed NIH 3T3 Sarcoma Cell Lines into Highly Metastasizing Tumors by Fusion with Lymphoid cells," Abstract 373, <u>Proceedings of the American Association for Cancer Research</u> , 1993, 34:63	
	44	S. ROSENBERG et al, "Special Report - Observations on the Systemic Administration of Autologous Lymphokine- activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer," <u>The New England Journal of Medicine</u> , 1985, 313(23):1485-1492	

Examiner
Signature

Yvonne Eder

Date

Considered

3/22/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)
Approved for use through 10/31/99, OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/110,376
		Filing Date	May 12, 1998
		First Named Inventor	Cohen
		Group Art Unit	1643
		Examiner Name	
Sheet 4 of 6	Attorney Docket Number		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1 of 2	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HE	23	K. MAYER et al, "An Essential cis-acting Element of the 1ck 3' Promoter Regulates the Expression of p56 ^{lck} in Metastatic Colorectal Cancer Cells," <i>Int. J. Oncology</i> , 1993, 3:369-373	
	24	M. OMARY et al, "Biochemical and Morphological Differentiation of the Human Colonic Cell Line SW620 in the Presence of Dimethylsulfoxide," <i>J. Cellular Biochemistry</i> , 1992, 48:316-323	
	25	S. COHEN et al, "Role of Asialo-Gm1 Positive Liver Cells from Athymic Nude or Polyinosinic-polycytidylic Acid-Treated Mice in Suppressing Colon-derived Experimental Hepatic Metastasis," <i>Cancer Res.</i> , 1990, 50:1834-1840	
	26	C. MALLICK et al, "Rearrangement and Diversity of T Cell Receptor B Chain Genes in Thymocytes: A Critical Role for the B Chain in Development," <i>Cell</i> , 1993, 73:513-519	
	27	F. VIDAL-VANACLOCHA et al, "Role of Periportal and Perivenous Sinusoidal Endothelial Cells in Hepatic Homing of Blood and Metastatic Cancer Cells," <i>Seminars in Liver Disease</i> , 1993, 13:60-71	
	28	M. COHN et al, "The Differentiation Antigen Ly-6E.1 is Expressed in Mouse Metastatic Tumor Cell Lines," <i>FEBS Letters</i> , 1997, 403:181-185	
	29	J. VINEY et al, "Generation of Monoclonal Antibodies Against a Human T Cell Receptor B Chain Expressed in Transgenic Mice," <i>Hybridoma</i> , 1992, 11:701-713	
	30	N. TOMITA et al, "Isolation and Characterization of a Highly Malignant Variant of the SW480 Human Colon Cancer Cell Line," <i>Cancer Research</i> , 1992, 52:6840-6847	
	31	M. O'REILLY, "Angiostatin Induces and Sustains Dormancy of Human Primary Tumors in Mice," <i>Nature Medicine</i> , 1996, 2(6):689-692	
	32	M. DOHLSTEN et al, "Human Major Histocompatibility Complex Class II-negative Colon Carcinoma Cells Present Staphylococcal Superantigens to Cytotoxic T-lymphocytes: Evidence for a Novel Enterotoxin Receptor," <i>Eur. J. Immunol.</i> , 1991, 21:1229-1233	
HE	33	J. LAMPHEAR, "Intercellular Adhesion Molecule-1 and Leukocyte Function-associated Antigen-3 Provide Superantigen-induced T Lymphocyte Proliferation in the Absence of a Specific Presenting Molecule," <i>The Journal of Immunology</i> , 1998, 160:615-623	

Examiner Signature	<i>Yumme Cifer</i>	Date Considered	3/22/00
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

E 6

Attorney Docket Number

Complete If Known

Application Number

09/110,376

Filing Date

May 12, 1998

First Named Inventor

Cohen

Group Art Unit

164.3

Examiner Name

Attorney Docket Number

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

4 some Epters

Date _____

Considered

3/22/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known	
		Application Number	09/110,376
		Filing Date	May 12, 1998
		First Named Inventor	Cohen
		Group Art Unit	1643
		Examiner Name	
Sheet	1	of	6
		Attorney Docket Number	

[illegible][illegible]

Examiner Signature	<i>Yvonne G. Lee</i>	Date Considered	. 3/22/00
-----------------------	----------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**